CircFAT1 is Overexpressed in Colorectal Cancer and Suppresses Cancer Cell Proliferation, Invasion and Migration by Increasing the Maturation of MiR-10a

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Jun 9

PMID 34103986

Citations 3

Authors

Meng Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: It has been reported that circFAT1 plays opposite roles in gastric cancer and osteosarcoma. This study aimed to explore the involvement of circFAT1 in colorectal cancer (CRC).

Patients And Methods: Paired CRC and non-tumor tissues from 64 CRC patients were subjected to RNA preparations and RT-qPCRs to determine the expression of circFAT1, premature miR-10a, and mature miR-10a. In CRC cells, the effects of circFAT1 overexpression on miR-10a maturation were analyzed by determining the expression of both premature miR-10a and mature miR-10a using RT-qPCRs. The role of circFAT1 and miR-10a in regulating the proliferation, invasion, and migration of CRC cells was analyzed by BrdU and Transwell assays, respectively.

Results: We found that circFAT1 was upregulated in CRC. Mature miR-10a, but not premature miR-10a, was overexpressed in CRC and positively correlated with circFAT1. CircFAT1 overexpression increased the expression of mature miR-10a, but not premature miR-10a. Overexpression of circFAT1 and miR-10a increased cell proliferation, invasion and migration, and miR-10a inhibitor suppressed cell behaviors and reversed the effects of circFAT1 overexpression.

Conclusion: circFAT1 is overexpressed in CRC and may suppress CRC cell proliferation, invasion and migration by increasing miR-10a maturation.

Citing Articles

Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.

Heydarnia E, Dorostgou Z, Hedayati N, Mousavi V, Yahyazadeh S, Alimohammadi M Cell Commun Signal. 2024; 22(1):107.

PMID: 38341592 PMC: 10859032. DOI: 10.1186/s12964-024-01494-0.

Advances in targeting of miR‑10‑associated lncRNAs/circRNAs for the management of cancer (Review).

Gao S, Liu S, Wei W, Qi Y, Meng F Oncol Lett. 2023; 25(3):89.

PMID: 36817057 PMC: 9931999. DOI: 10.3892/ol.2023.13675.

CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering miR-7 from Repressing IRS2-ERK-mediated CCND1 Expression.

Peng H, Zhang W, Dong H, Yuan J, Li Y, Li F Int J Biol Sci. 2022; 18(10):3944-3960.

PMID: 35844799 PMC: 9274483. DOI: 10.7150/ijbs.70889.

References

Edwards M, Chadda S, Zhao Z, Barber B, Sykes D . A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 2011; 14(2):e31-47. PMC: 3562494. DOI: 10.1111/j.1463-1318.2011.02765.x. View

El-Shami K, Oeffinger K, Erb N, Willis A, Bretsch J, Pratt-Chapman M . American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin. 2015; 65(6):428-55. PMC: 5385892. DOI: 10.3322/caac.21286. View

Heinemann V, Douillard J, Ducreux M, Peeters M . Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Cancer Treat Rev. 2013; 39(6):592-601. DOI: 10.1016/j.ctrv.2012.12.011. View

Shang Q, Yang Z, Jia R, Ge S . The novel roles of circRNAs in human cancer. Mol Cancer. 2019; 18(1):6. PMC: 6325800. DOI: 10.1186/s12943-018-0934-6. View

Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View

De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S . KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2010; 12(6):594-603. DOI: 10.1016/S1470-2045(10)70209-6. View

Liu Y, Zhang Y, Wu H, Li Y, Zhang Y, Liu M . miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis. Cell Death Dis. 2017; 8(4):e2739. PMC: 5477594. DOI: 10.1038/cddis.2017.61. View

Sanna V, Pala N, Sechi M . Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 2014; 9:467-83. PMC: 3896284. DOI: 10.2147/IJN.S36654. View

Gu H, Cheng X, Xu J, Zhou K, Bian C, Chen G . Circular RNA circFAT1(e2) Promotes Osteosarcoma Progression and Metastasis by Sponging miR-181b and Regulating HK2 Expression. Biomed Res Int. 2020; 2020:3589871. PMC: 7378629. DOI: 10.1155/2020/3589871. View

10.

Guo Y, Xu F, Lu T, Duan Z, Zhang Z . Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012; 38(7):904-10. DOI: 10.1016/j.ctrv.2012.04.007. View

11.

Fang J, Hong H, Xue X, Zhu X, Jiang L, Qin M . A novel circular RNA, circFAT1(e2), inhibits gastric cancer progression by targeting miR-548g in the cytoplasm and interacting with YBX1 in the nucleus. Cancer Lett. 2018; 442:222-232. DOI: 10.1016/j.canlet.2018.10.040. View

12.

Zhou R, Wu Y, Wang W, Su W, Liu Y, Wang Y . Circular RNAs (circRNAs) in cancer. Cancer Lett. 2018; 425:134-142. DOI: 10.1016/j.canlet.2018.03.035. View

13.

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

14.

Liu S, Zheng R, Zhang M, Zhang S, Sun X, Chen W . Incidence and mortality of colorectal cancer in China, 2011. Chin J Cancer Res. 2015; 27(1):22-8. PMC: 4329182. DOI: 10.3978/j.issn.1000-9604.2015.02.01. View

15.

Long M, Wu F, Li P, Liu M, Li X, Tang H . MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012; 324(2):186-96. DOI: 10.1016/j.canlet.2012.05.022. View

16.

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D . Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii1-9. DOI: 10.1093/annonc/mdu260. View

17.

Lei B, Tian Z, Fan W, Ni B . Circular RNA: a novel biomarker and therapeutic target for human cancers. Int J Med Sci. 2019; 16(2):292-301. PMC: 6367529. DOI: 10.7150/ijms.28047. View